Zusammenfassung
In 33 Fallberichten wurde die therapeutische oder prophylaktische Anwendung einer Betulin-Emulsion in Fertigpräparaten bei strahlen- oder chemotherapeutisch geschädigter Haut geprüft. 14 Patienten wurden nach dem Auftreten von Hautveränderungen mit Betulin-Emulsion gepflegt, weitere 19 Patienten erhielten die Emulsion in 2 verschiedenen Zubereitungen prophylaktisch. Die therapeutische Behandlung über 7 Tage reduzierte die Hautsymptome deutlich, während die prophylaktische Applikation die Haut in allen Fällen vor starken Veränderungen schützte. Damit ist die Betulin-Emulsion eine vielversprechende Möglichkeit bei der Pflege strahlen- und chemotherapeutisch geschädigter Haut.
Summary
Betulin emulsions in therapy and prophylaxis of skin alterations caused by chemotherapy and radiation. First experiences.
In 33 case studies, the therapeutic and prophylactic use of a betulin emulsion in ready-to-use preparations on skin alterations caused by chemotherapy and radiation was examined. 14 patients were treated after appearance of skin alterations and 19 patients received prophylactic application. The therapeutic application of betulin emulsion causes a down-staging of the alterations, whereas prophylactic treatment protected the skin in all cases. The present results suggest that the use of betulin emulsion is a promising treatment option of skin alterations caused by chemotherapy or radiation.
Schlüsselwörter
Betulin -
Betula alba
- Hand-Fuß-Syndrom - Radiochemotherapie - Dermatologie
Key words
Betulin -
Betula alba
- hand-and-foot syndrome - chemotherapy - radiation - dermatology
Literatur
-
r1
Cox JD, Stetz J, Pajak TF..
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys.
1995;
31
1341-1346
-
r2
Archambeau JO, Pezner R, Wasserman T..
Pathophysiology of irradiated skin and breast.
Int J Radiat Oncol Biol Phys.
1995;
31
1171-1185
-
r3
Glean E, Edwards S, Faithfull S.
, et al.
Intervention for acute radiotherapy induced skin reactions in cancer patients: the development of a clinical guideline recommended for use by the college of radiographers.
J Radiother Pract.
2000;
2
75-84
-
r4
Hopewell JW..
The skin: its structure and response to ionizing radiation.
Int J Radiat Biol.
1990;
57
751-773
-
r5
Campbell IR, Illingworth MH..
Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial.
Clin Oncol (R Coll Radiol).
1992;
4
78-82
-
r6 European Medicines Agency. Produktinformation Caelyx. Revision 18 – published 09/03/09. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000089/WC500020180.pdf
-
r7
Hoff PM, Ansari R, Batist G.
, et al.
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
J Clin Oncol.
2001;
19
2282-2292
-
r8
Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN..
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine.
Cancer.
1998;
82
965-969
-
r9
Van Cutsem E, Verslype C, Tejpar S..
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Semin Oncol.
2005;
32
43-51
-
r10
Lin E, Morris JS, Ayers GD..
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Oncology (Williston Park).
2002;
16
31-37
-
r11
Nagore E, Insa A, Sanmartin O..
Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management.
Am J Clin Dermatol.
2000;
1
225-234
-
r12 AMWF – Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Leitlinien für Diagnostik und Therapie Radioonkologie. Leitlinien-Register Nr. 052/014 (gültig bis 12/2011). http://awmf.org/
-
r13
Laszczyk M, Jäger S, Simon-Haarhaus B.
, et al.
Physical, chemical and pharmacological characterization of a new oleogel-forming triterpene extract from the outer bark of birch (Betulae cortex).
Planta Med.
2006;
72
1389-1395
-
r14
Daniels R, Laszczyk M..
Betulin für tensidfreie Emulsionen.
Pharmazeutische Zeitung.
2008;
Nr. 11
34-36
-
r15
Laszczyk MN..
Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy.
Planta Med.
2009;
75
1549-1560
-
r16
Woelfle U, Laszczyk MN, Kraus M.
, et al.
Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6.
J Invest Dermatol.
2010;
130
113-123
-
r17
Laszczyk MN, Reitenbach-Blindt I, Gehring W..
Regenerative und anti-entzündliche Effekte von Betulin-Emulsionen bei gestörter epidermaler Barrierefunktion.
Akt Derm.
2009;
35
1-5
-
r18
Laszczyk M, Phan NQ, Siepmann D.
, et al.
Topical therapy with the betulin based triterpene extract (TE) in patients with chronic pruritus.
Planta Med.
2009;
75
, Abstract
PI16
Dr. Melanie Laszczyk
Birken GmbH
Streiflingsweg 11
75223 Niefern-Öschelbronn
Email: m.laszczyk@birken-gmbh.de
Online
http://dx.doi.org/10.1055/s-0030-1262390
